Home » Market News » DirectorsTalk Highlights » pre|CISION™ technology
Avacta Group Plc

pre|CISION™ technology

Avacta’s proprietary pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein (FAPα) which is highly upregulated in the tumour microenvironment of most solid tumours compared with healthy tissues. The pre|CISION substrate can be utilised in a drug conjugate linker or to generate chemotherapy pro-drugs that are only activated in the tumour.

When added to a chemotoxin, the pre|CISION substrate prevents the chemotoxin from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this pro-drug approach, the systemic exposure to the chemotoxin is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments is improved.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.